Guggenheim Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $21
Guggenheim analyst Subbu Nambi initiates coverage on Freenome (NASDAQ:FRNM) with a Buy rating and announces Price Target of $21.
Read original at benzingaStocks · News reference
Freenome Receives FDA Breakthrough Device Designation For Its Investigational Lung Cancer Screening Test SimpleScreen Lung
The designation applies to the proposed use of SimpleScreen Lung in adults ages 50 to 80 who have at least a 20 pack-year smoking history and are not currently participating in guideline-recommended lung cancer
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 12, 2026, 1:02 PM
- Checked
- Aug 12, 2026, 1:02 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Frenome Files Prospectus Related To The Offer And Sale From Time To Time By The Selling Securityholders Of Up To 75,188,742 Shares Of Common Stock
https://www.sec.gov/ix?doc=/Archives/edgar/data/0002017526/000114036126033585/ny20080283x1_s1.htm
Read original at benzingaTD Cowen Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17
TD Cowen analyst Dan Brennan initiates coverage on Freenome (NASDAQ:FRNM) with a Buy rating and announces Price Target of $17.
Read original at benzingaFreenome shares are trading higher after BTIG and Jefferies initiated coverage on the stock with a Buy rating and announced a $17 price target.
Read original at benzinga